Completed PHASE1/PHASE2 NCT00100750

Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer

Gemcitabine and R115777 Combination Therapy for Metastatic Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Breast Carcinoma Stage IV Breast Cancer

Interventions Gemcitabine Hydrochloride Laboratory Biomarker Analysis Tipifarnib

Updated 6 times since 2017 Last updated: Jan 12, 2015 Started: Sep 30, 2005 Primary completion: Oct 31, 2007 Completion: Jan 31, 2010

A PHASE1/PHASE2 clinical study on Recurrent Breast Carcinoma and Stage IV Breast Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 6 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States